NCT02209779View on ClinicalTrials.gov

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

June 30, 2002

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

BIBR 796 BS

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02209779 - Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter